The Next Frontier of Pandemic Preparedness

This NYSE biotech firm just unveiled a game-changing antiviral candidate.

We’ve all seen firsthand the power a virus can exert on the planet — and the market.

The COVID-19 pandemic was a Black Swan event. It would’ve been near-impossible to see the telltale signs, except in retrospect. But you know what they say. Fool me once, shame on you. Fool me twice…

Fortunately, one company is making sure the world isn’t caught off guard again. And it may present the perfect opportunity for investors to safeguard their portfolios too.

NanoViricides (NYSE: NNVC)’s broad-spectrum antiviral drug NV-387 is poised to cause a revolution in the treatment of viral diseases.

Imagine a single drug that could treat the bird flu, RSV, COVID, long COVID, and even MPox and Smallpox infections caused by hMPXV — for which there is currently no pharmaceutical treatment available.

That’s what NanoViricides (NYSE: NNVC) plans to develop in NV-387.

The drug has already been found to be able to cure lethally RSV-infected mice, and now the company is working towards a Phase II clinical trial to evaluate its effectiveness in treating MPox patients.

Don’t overlook the next frontier of pandemic preparedness. See how NNVC’s treatment could lead to an exponentially safer society — and maybe even exponential growth for the company.

This message includes a paid advertisement for NanoViricides (NYSE: NNVC). The Street Sheet (SS) receives a flat fee totaling up to $1,500 from Interactive Offers. Other than the compensation received for this advertisement sent to subscribers, The Street Sheet and its principals are not affiliated with Cadiz Inc. The Street Sheet and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. The Street Sheet is a research service not owned or managed by registered brokers and therefore this site does not make any investment recommendations. The information provided in this newsletter is not guaranteed as to the accuracy or completeness. Each user of SS chooses to do trades at their sole discretion and risk. SS is not responsible for gains/losses that may result in the trading of these securities. This newsletter includes paid advertisements. The source of all third-party content in which SS receives some sort of compensation is clearly and prominently identified herein as "ad", "Sponsored", or “Together With”. Although we have sent you these advertisements, SS does not specifically endorse any third-party product nor is it responsible for the content, the accuracy, or the completeness of the advertisement or the experience with the third-party advertiser. Furthermore, we make no guarantee or warranty about what is in the advertisement. All investments involve risk, losses may exceed the principal invested, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. This communication from The Street Sheet is for informational purposes only. It is not intended to serve as a recommendation to buy, sell, or hold any security and is not an offer or sale of a security. Information contained within should not be perceived as a research report and is not intended to serve as the basis for any investment decision. Any third-party views reflected herein do not reflect the opinion of The Street Sheet. All investments involve risk and the past performance of a security does not guarantee future results or returns. There is always the potential for financial loss when investing in securities or other financial products. The information contained in this newsletter is subject to change without notice, and we do not undertake any obligation to update it. Readers are encouraged to conduct their own research and due diligence and seek advice from licensed professionals regarding their specific financial needs and circumstances. By reading this newsletter, you agree to hold us harmless from any and all losses, liabilities, costs, or expenses arising from your use or reliance on the information provided. There is no warranty as to the accuracy or completeness of the factual matters included in any advertisement or sponsored content in the newsletter. You have not performed any research on any entity, or its business, that advertises or submits any sponsored content. The Street Sheet is reader-supported. When you buy through links on our site, we may earn a commission.

Reply

or to participate.